Liquidia Settles Lung Drug Dispute With United Therapeutics for $381 Million
The settlement ends six lawsuits over patents, trade secrets and contracts. Liquidia shares jumped nearly 40% in premarket trading Wednesday.
Liquidia (NASDAQ:LQDA) shares rose nearly 40% in premarket trading on Wednesday after the drugmaker resolved a years-long legal dispute with United Therapeutics (NASDAQ:UTHR) over its lung disease drug. Announced late on Tuesday, the settlement concludes six lawsuits involving patents, trade secrets and contracts.